Pink SheetA social media post by Sprout Pharmaceuticals ’ founder and CEO for the hypoactive sexual desire disorder drug Addyi (flibanserin) failed to include risk information, the US Food and Drug Administrat
Pink SheetCongress and now some in the Trump Administration want to end tax breaks for pharmaceutical direct-to-consumer advertising, although the deduction may be difficult to remove. Health and Human Services
Pink SheetPromotions for Sarfez Pharmaceuticals ’ diuretic Soaanz (torsemide) make misleading efficacy claims and understate risks, the US FDA Office of Prescription Drug Promotion said in its first warning l
Pink SheetA promotional slide deck for Mayne Pharma ‘s Nextstellis oral contraceptive (drospirenone/estetrol) misleadingly suggests it is safer than other estrogen-containing products, the US Food and Drug Adm